Is ADC Therapeutics SA (ADCT) a Strong Momentum Stock Worth Buying?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 15 2025
0mins
Should l Buy ADCT?
Source: NASDAQ.COM
Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation that they will continue to rise. Investors often face challenges in identifying the best metrics to gauge momentum, but tools like the Zacks Momentum Style Score can help.
ADC Therapeutics Performance: ADC Therapeutics SA (ADCT) has a Momentum Style Score of A and a Zacks Rank of #2 (Buy). The stock has shown significant price increases, with a 28.57% rise over the past week and a 123.81% increase over the last year, outperforming the S&P 500.
Earnings Estimates and Volume: Recent earnings estimate revisions for ADCT have been positive, with two estimates moving higher, contributing to a consensus estimate improvement. Additionally, the stock's average trading volume of 1,634,451 shares indicates strong market interest.
Investment Recommendations: Zacks Investment Research highlights ADCT as a promising stock for near-term gains, alongside other selected stocks that are expected to perform well in the coming months, with previous recommendations achieving substantial returns.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADCT
Wall Street analysts forecast ADCT stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.020
Low
5.00
Averages
7.33
High
10.00
Current: 4.020
Low
5.00
Averages
7.33
High
10.00
About ADCT
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADC Therapeutics Grants Stock Options to New Employees
- Employee Incentive Program: On February 2, 2026, ADC Therapeutics granted stock options for 308,000 common shares to seven new employees as a significant inducement for their employment, aimed at motivating them to contribute meaningfully to the company's success.
- Grant Details: The stock options will vest 25% on the first anniversary of the grant date, with 1/48th vesting monthly thereafter, ensuring full vesting by the fourth anniversary, which encourages employee retention.
- Compliance Assurance: The grants were made in reliance on the employment inducement exemption under NYSE's Listed Company Manual Rule 303A.08, ensuring that the company meets regulatory requirements while incentivizing its workforce.
- Company Background: ADC Therapeutics focuses on the development of antibody-drug conjugates (ADCs), with its product ZYNLONTA receiving accelerated approval from the FDA, highlighting the company's leadership in innovative drug development.
See More
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
- Surge in FDA Approvals: In 2025, over 50 FDA approvals were granted, with 20 in Q4 alone, indicating strong institutional confidence in late-stage platforms, which benefits Oncolytics Biotech by attracting increased investor interest.
- Leadership Enhancement: Oncolytics Biotech appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics, both bringing extensive late-stage clinical trial experience to drive complex multi-country registration trials.
- Impressive Clinical Data: In colorectal cancer patients, the combination of pelareorep and chemotherapy achieved a 33% response rate, significantly surpassing the traditional 6-11% response rate, showcasing its competitive edge and potential commercial value in the market.
- Phase 3 Trial Design Approved: Oncolytics Biotech has secured FDA approval for its Phase 3 trial design for pancreatic cancer, marking the imminent launch of its registration trial in this notoriously difficult-to-treat area, further solidifying its market position.
See More
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
- Surge in FDA Approvals: In 2025, over 50 FDA drug approvals were granted, with 20 in Q4 alone, indicating strong institutional confidence in late-stage platforms, positioning Oncolytics Biotech to benefit from increased capital inflow.
- Leadership Enhancement: Oncolytics Biotech announced the hiring of two key executives, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, whose extensive experience will enhance the company's execution in complex multi-country registration trials.
- Impressive Clinical Data: In colorectal cancer, pelareorep combined with chemotherapy achieved a 33% response rate, three times higher than traditional treatments, showcasing its competitive edge and likely attracting more investor interest.
- Regulatory Approval Secured: Oncolytics Biotech has received FDA approval for its Phase 3 trial design for pancreatic cancer, making it the only immunotherapy registration trial planned for this challenging disease, further solidifying its market position.
See More
ADC Therapeutics Faces Securities Fraud Investigation, Stock Drops 14.13%
- Investigation Launched: Pomerantz LLP is investigating whether ADC Therapeutics has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock volatility.
- Clinical Trial Data: On December 3, 2025, ADC released data from the LOTIS-7 trial indicating that 36.7% of patients experienced cytokine release syndrome; despite positive framing, the occurrence of adverse events could tarnish the company's reputation.
- Stock Price Reaction: Following the clinical data release, ADC's stock price fell by $0.65, a 14.13% drop, closing at $3.95 per share, reflecting market concerns about the company's future prospects.
- Legal Context: Pomerantz LLP, a prominent securities class action firm with over 85 years of experience, is dedicated to protecting investor rights, and adverse findings from the investigation could result in significant financial liabilities for the company.
See More
ADC Therapeutics Faces Securities Fraud Investigation as Stock Drops 14.13%
- Investigation Launched: Pomerantz LLP is investigating ADC Therapeutics for potential securities fraud, which could undermine investor confidence and lead to further stock price volatility.
- Clinical Trial Data Update: On December 3, 2025, ADC released data from the LOTIS-7 trial indicating that 36.7% of patients experienced cytokine release syndrome, and while the data was presented positively, the associated risks may affect market acceptance of its products.
- Stock Price Reaction: Following the release of adverse clinical data, ADC's stock price fell by $0.65, or 14.13%, closing at $3.95 per share on December 3, 2025, reflecting market concerns about the company's future prospects.
- Legal Implications: Pomerantz LLP, a prominent securities class action firm, may initiate legal proceedings against ADC, potentially impacting shareholder interests and the company's reputation.
See More
ADC Therapeutics Reports $73M Net Revenue for 2025 with Strong Cash Position
- Financial Performance: ADC Therapeutics anticipates net product revenue of approximately $73 million for 2025, up from $69.3 million in 2024, indicating sustained market demand in the antibody-drug conjugate sector.
- Cash Flow Outlook: As of December 31, 2025, the company reported cash and cash equivalents of about $261 million, expected to support operations at least until 2028, enhancing investor confidence in financial stability.
- Clinical Progress: The company expects to complete enrollment for LOTIS-7 in the first half of 2026 and release topline data for LOTIS-5 in Q2 2026, laying the groundwork for future regulatory submissions and market introduction.
- Market Opportunities: With potential compendia inclusion in 2027 and regulatory approvals for LOTIS-5, ADC Therapeutics is poised for accelerated revenue growth, further solidifying its leadership position in the antibody-drug conjugate market.
See More
ADC Therapeutics Grants Stock Options to New Employees
- Employee Incentive Program: On February 2, 2026, ADC Therapeutics granted stock options for 308,000 common shares to seven new employees as a significant inducement for their employment, aimed at motivating them to contribute meaningfully to the company's success.
- Grant Details: The stock options will vest 25% on the first anniversary of the grant date, with 1/48th vesting monthly thereafter, ensuring full vesting by the fourth anniversary, which encourages employee retention.
- Compliance Assurance: The grants were made in reliance on the employment inducement exemption under NYSE's Listed Company Manual Rule 303A.08, ensuring that the company meets regulatory requirements while incentivizing its workforce.
- Company Background: ADC Therapeutics focuses on the development of antibody-drug conjugates (ADCs), with its product ZYNLONTA receiving accelerated approval from the FDA, highlighting the company's leadership in innovative drug development.
See More
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
- Surge in FDA Approvals: In 2025, over 50 FDA approvals were granted, with 20 in Q4 alone, indicating strong institutional confidence in late-stage platforms, which benefits Oncolytics Biotech by attracting increased investor interest.
- Leadership Enhancement: Oncolytics Biotech appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics, both bringing extensive late-stage clinical trial experience to drive complex multi-country registration trials.
- Impressive Clinical Data: In colorectal cancer patients, the combination of pelareorep and chemotherapy achieved a 33% response rate, significantly surpassing the traditional 6-11% response rate, showcasing its competitive edge and potential commercial value in the market.
- Phase 3 Trial Design Approved: Oncolytics Biotech has secured FDA approval for its Phase 3 trial design for pancreatic cancer, marking the imminent launch of its registration trial in this notoriously difficult-to-treat area, further solidifying its market position.
See More
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
- Surge in FDA Approvals: In 2025, over 50 FDA drug approvals were granted, with 20 in Q4 alone, indicating strong institutional confidence in late-stage platforms, positioning Oncolytics Biotech to benefit from increased capital inflow.
- Leadership Enhancement: Oncolytics Biotech announced the hiring of two key executives, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, whose extensive experience will enhance the company's execution in complex multi-country registration trials.
- Impressive Clinical Data: In colorectal cancer, pelareorep combined with chemotherapy achieved a 33% response rate, three times higher than traditional treatments, showcasing its competitive edge and likely attracting more investor interest.
- Regulatory Approval Secured: Oncolytics Biotech has received FDA approval for its Phase 3 trial design for pancreatic cancer, making it the only immunotherapy registration trial planned for this challenging disease, further solidifying its market position.
See More
ADC Therapeutics Faces Securities Fraud Investigation, Stock Drops 14.13%
- Investigation Launched: Pomerantz LLP is investigating whether ADC Therapeutics has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock volatility.
- Clinical Trial Data: On December 3, 2025, ADC released data from the LOTIS-7 trial indicating that 36.7% of patients experienced cytokine release syndrome; despite positive framing, the occurrence of adverse events could tarnish the company's reputation.
- Stock Price Reaction: Following the clinical data release, ADC's stock price fell by $0.65, a 14.13% drop, closing at $3.95 per share, reflecting market concerns about the company's future prospects.
- Legal Context: Pomerantz LLP, a prominent securities class action firm with over 85 years of experience, is dedicated to protecting investor rights, and adverse findings from the investigation could result in significant financial liabilities for the company.
See More
ADC Therapeutics Faces Securities Fraud Investigation as Stock Drops 14.13%
- Investigation Launched: Pomerantz LLP is investigating ADC Therapeutics for potential securities fraud, which could undermine investor confidence and lead to further stock price volatility.
- Clinical Trial Data Update: On December 3, 2025, ADC released data from the LOTIS-7 trial indicating that 36.7% of patients experienced cytokine release syndrome, and while the data was presented positively, the associated risks may affect market acceptance of its products.
- Stock Price Reaction: Following the release of adverse clinical data, ADC's stock price fell by $0.65, or 14.13%, closing at $3.95 per share on December 3, 2025, reflecting market concerns about the company's future prospects.
- Legal Implications: Pomerantz LLP, a prominent securities class action firm, may initiate legal proceedings against ADC, potentially impacting shareholder interests and the company's reputation.
See More
ADC Therapeutics Reports $73M Net Revenue for 2025 with Strong Cash Position
- Financial Performance: ADC Therapeutics anticipates net product revenue of approximately $73 million for 2025, up from $69.3 million in 2024, indicating sustained market demand in the antibody-drug conjugate sector.
- Cash Flow Outlook: As of December 31, 2025, the company reported cash and cash equivalents of about $261 million, expected to support operations at least until 2028, enhancing investor confidence in financial stability.
- Clinical Progress: The company expects to complete enrollment for LOTIS-7 in the first half of 2026 and release topline data for LOTIS-5 in Q2 2026, laying the groundwork for future regulatory submissions and market introduction.
- Market Opportunities: With potential compendia inclusion in 2027 and regulatory approvals for LOTIS-5, ADC Therapeutics is poised for accelerated revenue growth, further solidifying its leadership position in the antibody-drug conjugate market.
See More
